🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Sponsor trial record
Trackers Companies Trial finder
Sponsor · clinical trials

BeiGene clinical trials

Source: ClinicalTrials.gov, U.S. National Library of Medicine — current trials in our China, USA and UK registers with BeiGene as lead sponsor. Synced 26 Sep 2026
13Current trials
3Recruiting now
19Drugs in these trials
3Trial registers
Maintained by Sreepriya Prasannan
MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist
Compiled from ClinicalTrials.gov and CTIS registry records · Last verified · Editorial standards
At a glance

BeiGene is the lead sponsor of 13 current clinical trials in our China, USA and UK registers. 3 are recruiting patients now. The most common phase is Phase 3. The drugs named most often in its trials are Tislelizumab, Zanubrutinib and BGB-A445. The most-studied condition is Small Lymphocytic Lymphoma.

ClinicalTrials.gov trials by status

  • Recruiting323%
  • Active, closed1077%

Trials by phase

  • Phase 3431%
  • Phase 1/2323%
  • Phase 2323%
  • Observational18%
  • Phase 118%
  • Phase 418%
01

Clinical trials sponsored by BeiGene

13 on ClinicalTrials.gov
StudyPhaseStatusStartRegisters
Observational Study Evaluating the Efficacy and Safety of Zanubrutinib in Participants With Waldenström Macroglobulinemia
NCT05640102 · ClinicalTrials.gov ↗ · Waldenstrom Macroglobulinemia
Observational Recruiting 2023-03 USA
Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader
NCT05294731 · ClinicalTrials.gov ↗ · B-cell Malignancy, Non-Hodgkin Lymphoma, Mantle Cell Lymphoma
Phase 1/2 Recruiting 2022-05 China
Tislelizumab (Anti-Programmed Cell Death Protein-1 (PD-1) Antibody) in MSI-H or dMMR Solid Tumors
NCT03736889 · ClinicalTrials.gov ↗ · MSI-H/dMMR Solid Tumors
Phase 2 Recruiting 2018-09 China
Maintenance Treatment With BGB-290 Versus Placebo in Participants With Platinum-sensitive Recurrent Ovarian Cancer
NCT03519230 · ClinicalTrials.gov ↗ · Ovarian Cancer
Drug: Pamiparib
Phase 3 Active, closed 2018-05 China
A Study Comparing Zanubrutinib With Bendamustine Plus Rituximab in Participants With Previously Untreated CLL or SLL
NCT03336333 · ClinicalTrials.gov ↗ · Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Phase 3 Active, closed 2017-10 UK, USA, China
A Study Investigating the Efficacy and Safety of Alcestobart (LBL-007) Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine in Participants With Unresectable or Metastatic Colorectal Cancer
NCT05609370 · ClinicalTrials.gov ↗ · Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer
Phase 1/2 Active, closed 2023-01 USA, China
A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer
NCT05635708 · ClinicalTrials.gov ↗ · Non-small Cell Lung Cancer, Metastatic Non-small Cell Lung Cancer
Phase 2 Active, closed 2023-03 USA, China
A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors
NCT06257264 · ClinicalTrials.gov ↗ · Breast Cancer, Small Cell Lung Cancer, Ovarian Cancer
Phase 1 Active, closed 2024-03 USA, China
A Study to Investigate the Antitumor Activity, Safety, Tolerability, and Pharmacokinetics of BGB-A445 in Combination With Tislelizumab in Participants With Select Advanced Solid Tumors.
NCT05661955 · ClinicalTrials.gov ↗ · Urothelial Carcinoma, Renal Cell Carcinoma, Melanoma
Phase 1/2 Active, closed 2023-01 China
Study of Tislelizumab in Combination With Chemotherapy Compared to Chemotherapy Alone for Participants With Urothelial Carcinoma
NCT03967977 · ClinicalTrials.gov ↗ · Urothelial Carcinoma
Phase 3 Active, closed 2019-05 China
A Study to Evaluate the Efficacy and Safety of Zanubrutinib in Chinese Adults With Treatment-Naive Waldenström Macroglobulinemia
NCT07169331 · ClinicalTrials.gov ↗ · Waldenström's Macroglobulinemia
Phase 4 Active, closed 2025-10 China
Study of BGB-11417 in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
NCT05479994 · ClinicalTrials.gov ↗ · Leukemia, Lymphoma, Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Phase 2 Active, closed 2022-10 China
Comparing the Efficacy and Safety of a New Additional Treatment With Tislelizumab in Non-Small Cell Lung Cancer (NSCLC)
NCT04379635 · ClinicalTrials.gov ↗ · Non Small Cell Lung Cancer
Phase 3 Active, closed 2020-05 China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

02

Drugs in BeiGene trials

19 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

03

Conditions in BeiGene trials

24 conditions
Small Lymphocytic Lymphoma2Ovarian Cancer2Urothelial Carcinoma2Chronic Lymphocytic Leukemia1Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer1Non-small Cell Lung Cancer1Metastatic Non-small Cell Lung Cancer1Waldenstrom Macroglobulinemia1Breast Cancer1Small Cell Lung Cancer1Gastric Cancer1Renal Cell Carcinoma1Melanoma1Non-mucosal Melanoma1B-cell Malignancy1Non-Hodgkin Lymphoma1Mantle Cell Lymphoma1Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma1Waldenström's Macroglobulinemia1Leukemia1Lymphoma1Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma1MSI-H/dMMR Solid Tumors1Non Small Cell Lung Cancer1
04

By trial register

RegisterTrialsRecruiting
Clinical trials in China122
Clinical trials in USA51
Clinical trials in UK10

A trial with sites in more than one country appears in each of those registers.

05

Other sponsors in Small Lymphocytic Lymphoma

SponsorTrials
Loxo Oncology5
BeOne Medicines3

Sponsors with the most current trials registered for this condition.

06

Questions about BeiGene trials

How many clinical trials does BeiGene sponsor?

BeiGene is the lead sponsor of 13 current trials on ClinicalTrials.gov in our China, USA and UK registers, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are BeiGene trials recruiting?

Yes. 3 of its 13 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is BeiGene testing?

Its current trials name 19 drugs and biologicals as interventions. The most frequent are Tislelizumab (4), Zanubrutinib (3), BGB-A445 (2), Carboplatin (2) and Cisplatin (2). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

Approvals, shortages and trials, every Friday

One email a week with new EMA and FDA approvals, EU and US medicine shortages, how many trials are recruiting in Ireland, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.